News | February 18, 2008

Bioabsorable Stent May Reduce MACE Related to DES

February 19, 2008 – A novel, fully bioabsorbable salicylate-based stent offers the potential to reduce adverse events associated with current drug-eluting stents (DES) and could be very beneficial to patients with coronary heart disease, according to a presentation at the Cardiovascular Revascularization Therapies 2008 (CRT) symposium.

Refat Jabara, M.D., of the scientific team from Atlanta-based Saint Joseph’s Translational Research Institute (SJTRI), presented his abstract "Novel Anti-Inflammatory Salicylate-Based Bioabsorbable Drug-Eluting Polymeric Coating" from the podium during oral presentations of the 'Best Ten Abstracts' category. Dr. Jabara received Top Five Abstract Award honors for the work from the course chairman, Ron Waksman, M.D.

“At SJTRI, we are in the process of evaluating several variations of the next generation of intravascular stents. As demonstrated in this study, the technology of a fully bioabsorbable stent platform could lead to dramatic advances in the clinical treatment of patients with coronary heart disease. I am fortunate to be able to contribute to the assessment of these devices and the impact that they may have on the health and welfare of patients around the world,” said Dr. Jabara.

For more information: www.crtonline.org

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init